Illexcor Therapeutics, Inc.

Richmond, VA

UEI
GFKZPH9N1VX3
CAGE
88YN7
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
Biotech Center, 800 E Leigh St #19, Richmond, VA 23298, USA
Website
illexcor.com
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Novel therapeutic approach for severe ards with a potent pharmacologic allosteric hemoglobin modifier - acute… R44HL156334 National Heart Lung and Blood Institute (NIH) $3,097,413
Novel therapeutic approach for severe ards with a potent pharmacologic allosteric hemoglobin modifier - acute… R43HL156334 National Heart Lung and Blood Institute (NIH) $1,193,636
Rapid development of a lead aromatic aldehyde derivative with both oxygen dependent and novel, oxygen independent… R44HL154864 National Heart Lung and Blood Institute (NIH) $3,370,646
Rapid development of a lead aromatic aldehyde derivative with both oxygen dependent and novel, oxygen independent… R43HL154864 National Heart Lung and Blood Institute (NIH) $299,984
Prodrugs and derivatives of hydroxymethylfurfural (5-HMF) to develop a novel, bioavailable treatment for sickle cell… R43HL150961 National Heart Lung and Blood Institute (NIH) $299,962

Similar vendors

Vendor Location Primary NAICS
IHP Therapeutics Inc. UEI MASZJLS7DHK3 San Carlos, CA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Covenant Therapeutics LLC UEI KKJLPNVZZWT2 Charlottesville, VA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Thetis Pharmaceuticals LLC UEI QBDWD3M7YKM9 Deep River, CT —
Max Biopharma, Inc. UEI NZ8XY5DKRAD3 Santa Monica, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Advac Therapeutic LLC UEI JXDHQYNC4JQ9 Philadelphia, PA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Illexcor Therapeutics LLC is a for-profit limited liability company focused on developing novel therapeutics, particularly for respiratory and blood disorders. Through federal grants from the National Institutes of Health, the company conducts biomedical research and development to advance new drug candidates and treatments for conditions like acute respiratory distress syndrome (ARDS) and sickle cell disease (SCD).

Illexcor has received over $5 million in NIH funding to support several R&D projects related to ARDS and SCD therapies. This includes developing a pharmacological treatment to improve oxygenation for ARDS patients using a hemoglobin modifier drug, assessing the efficacy of lead anti-sickling drug candidates in preclinical animal models of SCD, and exploring prodrugs to treat SCD. The company has served as the prime recipient on project grants from the NIH's National Heart, Lung and Blood Institute and works with academic partners on certain grants. Through this federal funding, Illexcor conducts preclinical research and testing to advance its pipeline of novel therapeutic candidates for respiratory and blood disorders.

Quick answers

Is Illexcor Therapeutics, Inc. registered in SAM.gov?

Yes. Illexcor Therapeutics, Inc.'s SAM.gov registration is active through July 10, 2027.

What is Illexcor Therapeutics, Inc.'s most recent federal award?

Illexcor Therapeutics, Inc.'s most recent federal grant award is Novel therapeutic approach for severe ards with a potent pharmacologic allosteric hemoglobin modifier - acute… (R44HL156334), from National Heart Lung and Blood Institute (NIH), on January 1, 2021.

On GovTribe

See Illexcor Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login